SML0189

Indinavir sulfate salt hydrate

≥98% (HPLC), powder, antiretroviral agent

• Synonym(e): 2,3,5-Trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide sulfate hydrate, Crixivan hydrate, L-735,524 hydrate, MK-639 hydrate
• Empirische Formel (Hill-System): C₃₆H₄₇N₅O₄·H₂SO₄ · xH₂O
• Molekulargewicht: 711.87 (anhydrous basis)
• UNSPSC Code: 51111800
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder
• Quality level: 100
• Storage condition: desiccated

Eigenschaften

• Produktname: Indinavir sulfate salt hydrate, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• storage condition: desiccated
• color: white to tan
• solubility: H₂O: ≥15 mg/mL
• originator: Merck & Co., Inc., Kenilworth, NJ, U.S.
• storage temp.: 2-8°C
• Quality Level: 100

Beschreibung

Application

Indinavir sulfate salt hydrate may be used in HIV-related cell signaling studies.

Biochem/physiol Actions

Indinavir sulfate is an antiretroviral; HIV Protease Inhibitor

Indinavir sulfate is an antiviral HIV protease inhibitor.

Indinavir sulfate suppresses the replication of HIV and is an important component of antiretroviral therapy for initial treatment of HIV infection. It is known to cause renal and urologic toxicity.[1]

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable